☰

Howard Mellor - Publications

Affiliations: 
2003-2009 University of Oxford, Oxford, United Kingdom 
Tree Info Similar researchers PubMed Report error

4/38 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2010 Rzymski T, Milani M, Pike L, Buffa F, Mellor HR, Winchester L, Pires I, Hammond E, Ragoussis I, Harris AL. Regulation of autophagy by ATF4 in response to severe hypoxia. Oncogene. 29: 4424-35. PMID 20514020 DOI: 10.1038/onc.2010.191  0.489
2010 Mellor HR, Rouschop KM, Wigfield SM, Wouters BG, Harris AL. Synchronised phosphorylation of BNIP3, Bcl-2 and Bcl-xL in response to microtubule-active drugs is JNK-independent and requires a mitotic kinase. Biochemical Pharmacology. 79: 1562-72. PMID 20100468 DOI: 10.1016/j.bcp.2010.01.019  0.674
2009 Milani M, Rzymski T, Mellor HR, Pike L, Bottini A, Generali D, Harris AL. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib. Cancer Research. 69: 4415-23. PMID 19417138 DOI: 10.1158/0008-5472.CAN-08-2839  0.554
2007 Mellor HR, Harris AL. The role of the hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer. Cancer Metastasis Reviews. 26: 553-66. PMID 17805942 DOI: 10.1007/s10555-007-9080-0  0.624
Low-probability matches (unlikely to be authored by this person)
2006 Modok S, Mellor HR, Callaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Current Opinion in Pharmacology. 6: 350-4. PMID 16690355 DOI: 10.1016/j.coph.2006.01.009  0.291
2011 Mellor HR, Bell AR, Valentin JP, Roberts RRA. Cardiotoxicity associated with targeting kinase pathways in cancer Toxicological Sciences. 120: 14-32. PMID 21177772 DOI: 10.1093/toxsci/kfq378  0.271
2008 Mellor HR, Callaghan R. Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology. 81: 275-300. PMID 18259091 DOI: 10.1159/000115967  0.238
2004 Mellor HR, Neville DCA, Harvey DJ, Platt FM, Dwek RA, Butters TD. Cellular effects of deoxynojirimycin analogues: Inhibition of N-linked oligosaccharide processing and generation of free glucosylated oligosaccharides Biochemical Journal. 381: 867-875. PMID 15128289 DOI: 10.1042/Bj20031824  0.235
2003 Mellor HR, Platt FM, Dwek RA, Butters TD. Membrane disruption and cytotoxicity of hydrophobic N-alkylated imino sugars is independent of the inhibition of protein and lipid glycosylation. The Biochemical Journal. 374: 307-14. PMID 12769816 DOI: 10.1042/Bj20030348  0.212
2007 Alderden RA, Mellor HR, Modok S, Hall MD, Sutton SR, Newville MG, Callaghan R, Hambley TW. Elemental tomography of cancer-cell spheroids reveals incomplete uptake of both platinum(II) and platinum(IV) complexes. Journal of the American Chemical Society. 129: 13400-1. PMID 17929931 DOI: 10.1021/ja076281t  0.199
2005 Mellor HR, Ferguson DJ, Callaghan R. A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs. British Journal of Cancer. 93: 302-9. PMID 16052217 DOI: 10.1038/sj.bjc.6602710  0.198
2015 Cross MJ, Berridge BR, Clements PJ, Cove-Smith L, Force TL, Hoffmann P, Holbrook M, Lyon AR, Mellor HR, Norris AA, Pirmohamed M, Tugwood JD, Sidaway JE, Park BK. Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury. British Journal of Pharmacology. 172: 957-74. PMID 25302413 DOI: 10.1111/Bph.12979  0.198
2020 Burton L, Scaife P, Paine SW, Mellor HR, Abernethy L, Littlewood P, Rauch C. Hydrostatic pressure regulates CYP1A2 expression in human hepatocytes via a mechanosensitive AhR-dependent pathway. American Journal of Physiology. Cell Physiology. PMID 32159360 DOI: 10.1152/ajpcell.00472.2019  0.191
2005 Mellor HR, Snelling S, Hall MD, Modok S, Jaffar M, Hambley TW, Callaghan R. The influence of tumour microenvironmental factors on the efficacy of cisplatin and novel platinum(IV) complexes. Biochemical Pharmacology. 70: 1137-46. PMID 16139250 DOI: 10.1016/j.bcp.2005.07.016  0.184
2002 Garner B, Mellor HR, Butters TD, Dwek RA, Platt FM. Modulation of THP-1 macrophage and cholesterol-loaded foam cell apolipoprotein E levels by glycosphingolipids. Biochemical and Biophysical Research Communications. 290: 1361-7. PMID 11820771 DOI: 10.1006/Bbrc.2002.6356  0.175
2007 Modok S, Scott R, Alderden RA, Hall MD, Mellor HR, Bohic S, Roose T, Hambley TW, Callaghan R. Transport kinetics of four- and six-coordinate platinum compounds in the multicell layer tumour model. British Journal of Cancer. 97: 194-200. PMID 17579620 DOI: 10.1038/sj.bjc.6603854  0.166
2017 Cove-Smith L, Schmitt M, Dive C, Backen A, Mescallado N, Roberts R, Mellor H, Morris D, Naish J, Jackson A, Kirk J, Hargreaves A, Galvin M, Smith S, Brocklehurst S, et al. 019 Chemotherapy-induced cardiotoxicity: could a translational cardiac MRI model help identify patients at risk? Heart. 103: A16-A17. DOI: 10.1136/heartjnl-2017-311399.19  0.152
2004 Mellor HR, Neville DCA, Harvey DJ, Platt FM, Dwek RA, Butters TD. Cellular effects of deoxynojirimycin analogues: Uptake, retention and inhibition of glycosphingolipid biosynthesis Biochemical Journal. 381: 861-866. PMID 15128268 DOI: 10.1042/Bj20031822  0.15
2006 Modok S, Hyde P, Mellor HR, Roose T, Callaghan R. Diffusivity and distribution of vinblastine in three-dimensional tumour tissue: experimental and mathematical modelling. European Journal of Cancer (Oxford, England : 1990). 42: 2404-13. PMID 16901688 DOI: 10.1016/j.ejca.2006.05.020  0.146
2003 Butters TD, Mellor HR, Narita K, Dwek RA, Platt FM. Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 358: 927-45. PMID 12803927 DOI: 10.1098/Rstb.2003.1278  0.142
2006 Alderden RA, Mellor HR, Modok S, Hambley TW, Callaghan R. Cytotoxic efficacy of an anthraquinone linked platinum anticancer drug. Biochemical Pharmacology. 71: 1136-45. PMID 16458859 DOI: 10.1016/j.bcp.2005.12.039  0.135
2012 Priestley CC, Anderton M, Doherty AT, Duffy P, Mellor HR, Powell H, Roberts R. Epigenetics – relevance to drug safety science Toxicology Research. 1: 23-31. DOI: 10.1039/C2TX00003B  0.131
2011 Anderton MJ, Mellor HR, Bell A, Sadler C, Pass M, Powell S, Steele SJ, Roberts RR, Heier A. Induction of heart valve lesions by small-molecule ALK5 inhibitors. Toxicologic Pathology. 39: 916-24. PMID 21859884 DOI: 10.1177/0192623311416259  0.129
2002 Mellor HR, Nolan J, Pickering L, Wormald MR, Platt FM, Dwek RA, Fleet GW, Butters TD. Preparation, biochemical characterization and biological properties of radiolabelled N-alkylated deoxynojirimycins. The Biochemical Journal. 366: 225-33. PMID 11982484 DOI: 10.1042/Bj20020466  0.125
2014 Mellor HR. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations. Liver International : Official Journal of the International Association For the Study of the Liver. 34: e1-9. PMID 24393342 DOI: 10.1111/liv.12462  0.123
2017 Carr DF, Ayehunie S, Davies A, Duckworth CA, French S, Hall N, Hussain S, Mellor HR, Norris A, Park BK, Penrose A, Pritchard DM, Probert CS, Ramaiah S, Sadler C, et al. Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injury. Pharmacology & Therapeutics. PMID 28132905 DOI: 10.1016/j.pharmthera.2017.01.002  0.114
2014 Cove-Smith L, Woodhouse N, Hargreaves A, Kirk J, Smith S, Price SA, Galvin M, Betts CJ, Brocklehurst S, Backen A, Radford J, Linton K, Roberts RA, Schmitt M, Dive C, ... ... Mellor HR, et al. An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity. Toxicological Sciences : An Official Journal of the Society of Toxicology. 140: 3-15. PMID 24675088 DOI: 10.1093/toxsci/kfu057  0.113
2014 Barnes C, Kelsall J, Smith S, Cove-Smith L, Mellor H, Hargreaves A, Price S. Localisation of novel miRNA biomarkers of doxorubicin-induced cardiotoxicity in rats Toxicology Letters. 229: S245. DOI: 10.1016/J.TOXLET.2014.06.816  0.087
2011 Carmichael N, Bausen M, Boobis AR, Cohen SM, Embry M, Fruijtier-Pölloth C, Greim H, Lewis R, Bette Meek ME, Mellor H, Vickers C, Doe J. Using mode of action information to improve regulatory decision-making: an ECETOC/ILSI RF/HESI workshop overview. Critical Reviews in Toxicology. 41: 175-86. PMID 21401325 DOI: 10.3109/10408444.2010.541225  0.076
2000 Mellor HR, Adam A, Platt FM, Dwek RA, Butters TD. High-performance cation-exchange chromatography and pulsed amperometric detection for the separation, detection, and quantitation of N-alkylated imino sugars in biological samples. Analytical Biochemistry. 284: 136-42. PMID 10933866 DOI: 10.1006/Abio.2000.4678  0.07
1983 Lloyd D, Mellor H, Williams JL. Oxygen affinity of the respiratory chain of Acanthamoeba castellanii. The Biochemical Journal. 214: 47-51. PMID 6615472  0.06
2010 Nicolson TJ, Mellor HR, Roberts RRA. Gender differences in drug toxicity Trends in Pharmacological Sciences. 31: 108-114. PMID 20117848 DOI: 10.1016/j.tips.2009.12.001  0.057
2014 Roberts RA, Kavanagh SL, Mellor HR, Pollard CE, Robinson S, Platz SJ. Reducing attrition in drug development: smart loading preclinical safety assessment. Drug Discovery Today. 19: 341-7. PMID 24269835 DOI: 10.1016/j.drudis.2013.11.014  0.046
2010 Anderton MJ, Heier A, Bell A, Sadler C, Pass M, Powell S, Mellor HR, Roberts RA. Valvular heart lesions in Han Wistar rats dosed with ALK5 inhibitors Toxicology. 278: 343. DOI: 10.1016/J.TOX.2010.08.084  0.038
2006 Mellor HR, Davies LA, Caspar H, Pringle CR, Hyde SC, Gill DR, Callaghan R. Optimising non-viral gene delivery in a tumour spheroid model. The Journal of Gene Medicine. 8: 1160-70. PMID 16807955 DOI: 10.1002/jgm.947  0.037
2011 Mellor HR, Callaghan R. Accumulation and distribution of doxorubicin in tumour spheroids: the influence of acidity and expression of P-glycoprotein. Cancer Chemotherapy and Pharmacology. 68: 1179-90. PMID 21400240 DOI: 10.1007/s00280-011-1598-8  0.034
2007 Hall MD, Mellor HR, Callaghan R, Hambley TW. Basis for design and development of platinum(IV) anticancer complexes. Journal of Medicinal Chemistry. 50: 3403-11. PMID 17602547 DOI: 10.1021/jm070280u  0.028
2014 Kavanagh S, Mellor H, Pollard C, Robinson S, Platz S, Roberts R. Reducing attrition in drug development: Smart loading pre-clinical safety assessment Toxicology Letters. 229. DOI: 10.1016/J.Toxlet.2014.06.574  0.018
Hide low-probability matches.